WO2024241094 - IDENTIFICATION OF NOVEL BIOMARKERS FOR BREAST CANCER CTC CHARACTERIZATION

National phase entry is expected:
Publication Number WO/2024/241094
Publication Date 28.11.2024
International Application No. PCT/IB2024/000289
International Filing Date 21.05.2024
Title **
[English] IDENTIFICATION OF NOVEL BIOMARKERS FOR BREAST CANCER CTC CHARACTERIZATION
[French] IDENTIFICATION DE NOUVEAUX BIOMARQUEURS POUR LA CARACTÉRISATION DE CTC DU CANCER DU SEIN
Applicants **
SCREENCELL S.A. 62, rue de Wattignies 75012 Paris, FR
Inventors
NASERIAN, Sina 62, rue de Wattignies 75012 Paris, FR
Priority Data
63/468,041   22.05.2023   US
front page image
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing1959
EPO Filing, Examination12337
Japan Filing532
South Korea Filing575
USA Filing, Examination7635
MasterCard Visa

Total: 23038

Abstract[English] Provided herein are methods for identifying breast cancer in a subject, the methods comprising providing a biological sample from the subject and determining a differential level of at least one biomarker, wherein the differential level of the at least one biomarker compared to a healthy control or a reference value is indicative for the presence of breast cancer in the subject.[French] L'invention propose des procédés d'identification du cancer du sein chez un sujet, les procédés comprenant la fourniture d'un échantillon biologique provenant du sujet et la détermination d'un niveau différentiel d'au moins un biomarqueur, le niveau différentiel de l'au moins un biomarqueur par rapport à un témoin sain ou à une valeur de référence indiquant la présence d'un cancer du sein chez le sujet.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙